Suspension of trading
Valuation Eiger BioPharmaceuticals
Stocks
EIGR
US28249U2042
Biotechnology & Medical Research
|
Delayed
OTC Markets
01:27:07 28/09/24 am AEST
|
5-day change | 1st Jan Change | ||
| 8.500 USD | -.--% |
|
-.--% | - |
| 01/10/24 | Eiger BioPharmaceuticals Files for Chapter 11 Bankruptcy as Liquidation Plan Takes Effect | CI |
| 30/09/24 | Eiger BioPharmaceuticals, Inc. Went Out of Business | CI |
Company Valuation: Eiger BioPharmaceuticals
Data adjusted to current consolidation scope
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 194 | 365 | 399.8 | 176.3 | 52.01 | 9.964 |
| Change | - | 88.12% | 9.55% | -55.9% | -70.51% | -80.84% |
| Enterprise Value (EV) 1 | 119.3 | 302.2 | 303.5 | 120.1 | -11.28 | 25.32 |
| Change | - | 153.38% | 0.42% | -60.44% | -109.4% | 324.43% |
| P/E | -2.66x | -4.83x | -5.32x | -5.19x | -0.51x | -0.13x |
| PBR | 2.93x | 6.47x | 4.38x | 2.48x | 0.94x | -0.69x |
| PEG | - | 0.3x | 0.2x | 0.1x | -0x | 0x |
| Capitalization / Revenue | - | - | - | 14,522,675x | 3,856,989x | 631,735x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -2.34x | -4.39x | -4.9x | -1.57x | 0.12x | -0.35x |
| EV / EBIT | -2.34x | -4.39x | -4.88x | -1.56x | 0.12x | -0.35x |
| EV / FCF | -4.96x | -8.22x | -7.89x | -2.89x | 0.23x | -0.48x |
| FCF Yield | -20.2% | -12.2% | -12.7% | -34.6% | 426% | -210% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -114.6 | -92.5 | -69.34 | -29.98 | -69.74 | -50.78 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | 12.14 | 13.48 | 15.77 |
| EBITDA 1 | -50.99 | -68.84 | -61.98 | -76.66 | -92.45 | -71.51 |
| EBIT 1 | -51.05 | -68.9 | -62.15 | -76.94 | -92.74 | -71.79 |
| Net income 1 | -52.39 | -70.25 | -65.05 | -33.92 | -96.78 | -74.96 |
| Net Debt 1 | -74.73 | -62.75 | -96.33 | -56.28 | -63.29 | 15.36 |
| Reference price 2 | 304.800 | 447.000 | 368.700 | 155.700 | 35.400 | 6.735 |
| Nbr of stocks (in thousands) | 637 | 817 | 1,084 | 1,133 | 1,469 | 1,479 |
| Announcement Date | 14/3/19 | 13/3/20 | 9/3/21 | 10/3/22 | 17/3/23 | 8/4/24 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 12.59M | |
| 21.73x | 7.72x | 15.51x | 1.37% | 74.31B | |
| 29.59x | 8.5x | 26.48x | 0.04% | 56.95B | |
| 33.52x | 6.02x | 18.04x | 0.97% | 48.3B | |
| -21.51x | 223.61x | -23.09x | -.--% | 44.51B | |
| 34.27x | 3.31x | 14.29x | -.--% | 43.8B | |
| 47.24x | 5.47x | 29.99x | -.--% | 41.12B | |
| 27.63x | 7.93x | 20.48x | 0.41% | 31.07B | |
| 33.5x | 7.16x | 18.6x | -.--% | 28.97B | |
| -15.28x | 5.82x | -7.31x | -.--% | 24.53B | |
| Average | 21.19x | 30.62x | 12.55x | 0.31% | 39.36B | |
| Weighted average by Cap. | 22.51x | 31.17x | 13.62x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- EIGR Stock
- Valuation Eiger BioPharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
